ReviewInflammopharmacology2025
Is dolichol pathway dysfunction a significant factor in Alzheimer's disease?
Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The lithium-magnesium-zinc axis under stress: regulation of N-glycosylation-linked proteostasis and Alzheimer's disease.Inflammopharmacology · 2026Article
- From Isoprene Units to Polyprenols and Dolichols: 70 Years of Polyisoprenoid Biosynthesis Research.Cell biochemistry and biophysics · 2026Review
- Unlocking the Sugar Code: Implications and Consequences of Glycosylation in Alzheimer's Disease and Other Tauopathies.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several lines of evidence point to defects in the dolichol pathway as a major contributor to the development of Alzheimer's disease and inflammation associated with the unfolded protein response. In particular, zinc deficiency impairs formation of dolichol phosphate and low levels of pyridine nucleotides (NAD or NADPH), due to niacin deficiency, result in reduced conversion of polyprenol to dolichol phosphate, leading to reduced N-glycosylation of proteins. The magnesium-dependent transfer of N-acetyl-D-glucosamine-1-phosphate between dolichol phosphate (necessary for N-glycosylation) and UMP (required for O-glycosylation) by DPAGT1 ties dolichol phosphate biosynthesis to the balance between O- and N-glycosylation. Alteration of protein glycosylation would affect the folding, function, and physical properties (e.g., solubility) of many glycoproteins, such as UDP-glucuronosyltransferase (anosmia), amyloid precursor protein, tau, acetylcholine receptors, ligand-gated ion channels, voltage-gated ion channels, and G protein-coupled receptors. Three of the five best documented stress-induced nutritional deficiencies (i.e., zinc, niacin, and magnesium) would contribute to alterations in glycosylation of these and many other proteins involved in the progression of Alzheimer's disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.